» Articles » PMID: 28915706

The Role of Autophagy in Hepatocellular Carcinoma: Friend or Foe

Overview
Journal Oncotarget
Specialty Oncology
Date 2017 Sep 17
PMID 28915706
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

Autophagy is an evolutionarily conserved lysosome-dependent catabolic process which degrades cell's components in order to recycle substrates to exert optimally and adapt to tough circumstances. It is a critical cellular homeostatic mechanism with stress resistance, immunity, antiaging, and pro-tumor or anti-tumor effects. Among these, the role of autophagy in cancer is the most eye-catching that is not immutable but dynamic and highly complex. Basal autophagy acts as a tumor suppressor by maintaining genomic stability in normal cells. However, once a tumor is established, unbalanced autophagy will contribute to carcinoma cell survival under tumor microenvironment and in turn promote tumor growth and development. The dynamic role of autophagy can also apply on hepatocellular carcinoma (HCC). HCC is a highly malignant cancer with high morbidity and poor survival rate. Decline or overexpression of autophagic essential genes such as , or plays a key role in the occurrence and development of HCC but the exact mechanisms are still highly controversial. Signaling pathways or molecules involving in autophagy, for example PI3K/AKT/mTOR pathway, ERK/MAPK pathway, PERK pathway, p53, LncRNA PTENP1 (Long non-coding RNA PTENP1), microRNA-375 and so on, occupy an important position in the complex role of autophagy in HCC. Here, we discuss the dynamic role, the signaling pathways and the potential prognostic and therapy value of autophagy in HCC.

Citing Articles

ADSL promotes autophagy and tumor growth through fumarate-mediated Beclin1 dimethylation.

Wang L, Shi R, Wang S, Duan Y, Wang Z, Zheng P Nat Chem Biol. 2025; .

PMID: 39881212 DOI: 10.1038/s41589-024-01825-9.


Targeting p38γ synergistically enhances sorafenib-induced cytotoxicity in hepatocellular carcinoma.

Huang C, Zhang C, Li J, Duan Y, Tang Q, Bi F Cell Biol Toxicol. 2025; 41(1):35.

PMID: 39871031 PMC: 11772449. DOI: 10.1007/s10565-024-09979-x.


Icariin mediates autophagy and apoptosis of hepatocellular carcinoma cells induced by the β-catenin signaling pathway through lncRNA LOXL1-AS1.

Gao S, Zhang W, Dai J, Hu W, Xu Y, Yang H Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39812768 DOI: 10.1007/s00210-024-03692-6.


Digoxigenin activates autophagy in hepatocellular carcinoma cells by regulating the PI3K/AKT/mTOR pathway.

Ma M, Hu R, Huang Q, Li J, Lv M, Sun J Cancer Cell Int. 2024; 24(1):405.

PMID: 39696358 PMC: 11657738. DOI: 10.1186/s12935-024-03602-z.


Autophagy-based therapy for hepatocellular carcinoma: from standard treatments to combination therapy, oncolytic virotherapy, and targeted nanomedicines.

Rahdan F, Abedi F, Dianat-Moghadam H, Zamani Sani M, Taghizadeh M, Alizadeh E Clin Exp Med. 2024; 25(1):13.

PMID: 39621122 PMC: 11611955. DOI: 10.1007/s10238-024-01527-5.


References
1.
Feng Y, Yao Z, Klionsky D . How to control self-digestion: transcriptional, post-transcriptional, and post-translational regulation of autophagy. Trends Cell Biol. 2015; 25(6):354-63. PMC: 4441840. DOI: 10.1016/j.tcb.2015.02.002. View

2.
Xue F, Hu L, Ge R, Yang L, Liu K, Li Y . Autophagy-deficiency in hepatic progenitor cells leads to the defects of stemness and enhances susceptibility to neoplastic transformation. Cancer Lett. 2015; 371(1):38-47. DOI: 10.1016/j.canlet.2015.11.022. View

3.
Komatsu M, Waguri S, Ueno T, Iwata J, Murata S, Tanida I . Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J Cell Biol. 2005; 169(3):425-34. PMC: 2171928. DOI: 10.1083/jcb.200412022. View

4.
Chuma M, Terashita K, Sakamoto N . New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions. Hepatol Res. 2014; 45(10):E1-E11. DOI: 10.1111/hepr.12459. View

5.
Wilhelm S, Carter C, Tang L, Wilkie D, McNabola A, Rong H . BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64(19):7099-109. DOI: 10.1158/0008-5472.CAN-04-1443. View